Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of bapineuzumab when administered by
subcutaneous injection. The study is open only to subjects who participated in the preceding
double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab
for 3 years (156 doses). One dosage level will be included: 5 mg/week. All subjects will
receive active treatment (bapineuzumab) and no subjects will receive placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Collaborator:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC